<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329042</url>
  </required_header>
  <id_info>
    <org_study_id>UU01/47</org_study_id>
    <nct_id>NCT01329042</nct_id>
  </id_info>
  <brief_title>Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ouiheng International Healthcare Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChaingMai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prince Songkla University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siriraj Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ouiheng International Healthcare Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become
      the therapy of choice for renal stone. Although providing good results, stone recurrence is
      usually found as the therapies do not change the underlying metabolic abnormality. Among the
      metabolic disorders, hypocitraturia is an important risk factor for calcium nephrolithiasis.
      This study evaluate the preventive effects of potassium sodium citrate on stone recurrence as
      well as stone growth post ESWL or PCNL, in patients with calcium-containing stones.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of stone recurrence or stone growth</measure>
    <time_frame>12 months</time_frame>
    <description>The patients were evaluated at 6 months after the initial treatment for serum chemistry and urinalysis. After 12 months, all patients were evaluated for serum chemistry, urinalysis, 24-hour urine study and plain KUB.</description>
  </primary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Kidney Calculi</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium-sodium citrate</intervention_name>
    <description>The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment</description>
    <other_name>Uralyt-U</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  stone free or had residual calcium oxalate stone fragments with a less than 4 mm.
             diameter at eight weeks after ESWL or PCNL

        Exclusion Criteria:

          -  renal tubular obstruction

          -  serum creatinine &gt; 2 mg/dl

          -  urinary tract infection (bacteria &gt; 100,000 in urine culture)

          -  hypersensitive or contraindication to Potassium sodium hydrogen citrate

          -  insertion Double-J Stent

          -  history of arrhythmia, myocardial infarction or digitalis administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bannakij Lojanapiwat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Urology, Department of Surgery, Chiangmai University, Thailand</affiliation>
  </overall_official>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Bannakij Lojanapiwat</name_title>
    <organization>Division of urology, Department of surgery, Chiangmai University, Thailand</organization>
  </responsible_party>
  <keyword>Potassium sodium citrate</keyword>
  <keyword>stone recurrence</keyword>
  <keyword>ESWL</keyword>
  <keyword>PCNL</keyword>
  <keyword>Hypocitraturia</keyword>
  <keyword>intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 11, 2011</submitted>
    <returned>May 9, 2011</returned>
    <submitted>May 26, 2011</submitted>
    <returned>June 23, 2011</returned>
    <submitted>July 11, 2012</submitted>
    <returned>August 16, 2012</returned>
    <submitted>August 16, 2012</submitted>
    <returned>September 12, 2012</returned>
    <submitted>September 12, 2012</submitted>
    <returned>October 11, 2012</returned>
    <submitted>May 7, 2013</submitted>
    <returned>June 10, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

